Signal and Noise

Friday, October 9, 2026, 8:45 a.m. ET. The only thing that matters this morning is whether buyers believe the artificial intelligence spending machine after yesterday's wobble. Nasdaq 100 futures were up 0.75% and S&P 500 futures were up 0.38% at 8:40 a.m. ET, while the 10-year Treasury yield sat at 5.240%, according to Marketwall. That yield is Washington's ten-year borrowing cost, and it makes expensive stocks work harder to justify their price. Tech is bouncing, but one upbeat OpenAI (private) projection does not turn a rumor into audited cash. You should care because AI headlines keep steering this market.

Yesterday's Scoreboard

S&P 500: Down 0.47% to 7,765.36, with most damage concentrated in technology.
Nasdaq Composite: Down 1.25% to 27,193.34 as expensive growth stocks took the punch.
Dow Jones Industrial Average: Up 0.10% to 51,231.64, helped by industrial and energy names.
Best mover: Haemonetics (HAE) jumped 17.46% to $119.47 after CSL Plasma, owned by CSL Limited (CSL.AX), planned its equipment for all current U.S. plasma centers by end-2027. That means a larger rollout than traders priced.
Worst mover: Applied Optoelectronics (AAOI) sank 13.58% to $105.90 as traders dumped optical networking stocks after the OpenAI report. That means hot themes punish late buyers fast.

The Signal

AI gets a credibility test: OpenAI expects annualized revenue, the latest sales pace stretched across a full year, to reach at least $70 billion by year-end, up from roughly $50 billion at the end of September, Bloomberg reported. OpenAI confirmed neither figure, so the plain meaning is simple: chip stocks are bouncing on a forecast from fundraising talks, not money already in the bank.
Rates are still the bouncer: The 10-year Treasury yield was 5.240% at 8:40 a.m. ET, even with Nasdaq 100 futures up 0.75%. Plain meaning: borrowing stays expensive, and high-priced growth stocks do not get unlimited room just because one morning starts green.
Humana has real news: Humana (HUM) traded at $450.00, up 16.24%, at 8:41 a.m. ET on CNBC after saying 95% of its Medicare Advantage members will sit in plans rated four stars or better for 2027, versus 20% for 2026. Four-star plans can earn government bonuses, so future revenue may rise, mainly in 2028, not tomorrow.

The Noise

The $50 billion versus $70 billion OpenAI cage match: One number describes September's pace and the other describes a year-end expectation, with different treatment of partner sales. Treating them like a clean earnings miss and beat within 24 hours is financial theater wearing a calculator as a hat.
SpaceX has already killed the phone companies: SpaceX (private) agreed to buy up to 14 megahertz of nationwide 800 MHz spectrum, radio airwaves that travel well through walls, pending federal approval. AT&T (T) fell 6.84%, Verizon (VZ) fell 5.57%, and T-Mobile US (TMUS) fell 7.30% before the bell, but spectrum without a network is empty air. This is a threat, not an obituary.
Delta's revenue record fixes everything: Delta Air Lines (DAL) traded at $80.00, down 2.61%, at 8:40 a.m. ET after adjusted fuel expense rose 62% and full-year earnings guidance fell to $5.10 to $5.60 a share from $6.50 to $7.50. Plain meaning: full planes do not guarantee fat profits when the fuel bill eats the meal first.

On the Clock

10:00 a.m. ET, University of Michigan consumer sentiment: Economists expect 47.6, down from 48.1. The household mood survey can warn that spending may cool.
10:00 a.m. ET, University of Michigan inflation expectations: The prior one-year reading was 4.6%. Higher expectations give the Federal Reserve less room to cut rates.
4:00 p.m. ET, Boston Fed President Susan Collins: Listen for her view on another rate increase, because Fed words can reset borrowing costs before a vote.
Earnings: Delta reported before the bell, with its call at 10:00 a.m. ET. No major reports sit after the close, so the economic data gets the microphone once the Delta call ends.

IPO Watch

Retension Pharmaceuticals (RTSN): The blood-pressure drug developer priced 3.75 million shares at $12, within its $11 to $13 range, for today's debut. Watch whether it holds $12 after trading begins, because a break below the offer price means the first buyers are already underwater.
TRex Bio (TRXB): The autoimmune-drug developer priced 8.33 million shares at $14, the bottom of its range, for today's debut. Watch the opening volume and the $14 line, because early-stage biotech sells hope long before it sells a finished medicine.

Levels I Am Watching

SPY: $776.49 at 8:41 a.m. ET on CNBC. $777.09 is yesterday's ceiling where sellers showed up, traders call that resistance. $773.93 is yesterday's close and the first floor buyers need to defend, traders call that support.
QQQ: $752.67 at 8:41 a.m. ET on CNBC. $757.18 is yesterday's ceiling, while $747.58 is yesterday's close and first floor. Above the ceiling says muscle, below the floor says breakfast theater.
HUM: $450.00 at 8:41 a.m. ET on CNBC. $428.88 was the old 52-week high and now becomes the first serious floor to test, while $387.12 was yesterday's close. That empty stretch is a gap, where nobody traded during regular hours.

Term of the Day

Run rate: Stretch the latest month or quarter across a year to estimate the current sales pace. It is like judging a bar's yearly revenue from one packed Friday night, useful, but dangerous if Friday was special.

The Posture

Patient. Let the 10:00 a.m. data and the first hour expose whether this bounce has buyers or just better headlines.

Stay hungry, stay honest. DBTech45.